Design, Synthesis and Biological Evaluation of Novel MDH Inhibitors Targeting Tumor Microenvironmentopen access
- Authors
- Godesi, Sreenivasulu; Han, Jeong-Ran; Kim, Jang-Keun; Kwak, Dong-Ik; Lee, Joohan; Nada, Hossam; Kim, Minkyoung; Yang, Hyun-A; Im, Joo-Young; Ban, Hyun Seung; Lee, Chang Hoon; Choi, Yongseok; Won, Misun; Lee, Kyeong
- Issue Date
- May-2023
- Publisher
- MDPI
- Keywords
- MDH1/2; inhibitors; HIF-1 alpha; lung cancer
- Citation
- Pharmaceuticals, v.16, no.5, pp 1 - 35
- Pages
- 35
- Indexed
- SCIE
SCOPUS
- Journal Title
- Pharmaceuticals
- Volume
- 16
- Number
- 5
- Start Page
- 1
- End Page
- 35
- URI
- https://scholarworks.dongguk.edu/handle/sw.dongguk/19924
- DOI
- 10.3390/ph16050683
- ISSN
- 1424-8247
1424-8247
- Abstract
- MDH1 and MDH2 enzymes play an important role in the survival of lung cancer. In this study, a novel series of dual MDH1/2 inhibitors for lung cancer was rationally designed and synthesized, and their SAR was carefully investigated. Among the tested compounds, compound 50 containing a piperidine ring displayed an improved growth inhibition of A549 and H460 lung cancer cell lines compared with LW1497. Compound 50 reduced the total ATP content in A549 cells in a dose-dependent manner; it also significantly suppressed the accumulation of hypoxia-inducible factor 1-alpha (HIF-1a) and the expression of HIF-1a target genes such as GLUT1 and pyruvate dehydrogenase kinase 1 (PDK1) in a dose-dependent manner. Furthermore, compound 50 inhibited HIF-1a-regulated CD73 expression under hypoxia in A549 lung cancer cells. Collectively, these results indicate that compound 50 may pave the way for the development of next-generation dual MDH1/2 inhibitors to target lung cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > Department of Pharmacy > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.